Literature DB >> 7579455

Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.

B A Mehta1, I G Schmidt-Wolf, I L Weissman, R S Negrin.   

Abstract

Cytokine-induced killer (CIK) cells are non-major histocompatibility complex-restricted cytotoxic cells generated by incubation of peripheral blood lymphocytes with anti-CD3 monoclonal antibody (MoAb), interleukin-2 (IL-2), IL-1, and interferon-gamma. Cells with the greatest effector function in CIK cultures coexpress CD3 and CD56 surface molecules. CIK cell cytotoxicity can be blocked by MoAbs directed against the cell surface protein leukocyte function associated antigen-1 but not by anti-CD3 MoAbs. CIK cells undergo release of cytoplasmic cytotoxic granule contents to the extracellular space upon stimulation with anti-CD3 MoAbs or susceptible target cells. Maximal granule release was observed from the CD3+ CD56+ subset of effector cells. The cytoplasmic granule contents are lytic to target cells. Treatment of the effector cells with a cell-permeable analog of cyclic adenosine monophosphate (cAMP) inhibited anti-CD3 MoAb and target cell-induced degranulation and cytotoxicity of CIK cells. The immunosuppressive drugs cyclosporin (CsA) and FK506 inhibited anti-CD3-mediated degranulation, but did not affect cytotoxicity of CIK cells against tumor target cells. In addition, degranulation induced by target cells was unaffected by CsA and FK506. Our results indicate that two mechanisms of cytoplasmic granule release are operative in the CD3+ CD56+ killer cells; however, cytotoxicity proceeds through a cAMP-sensitive, CsA- and FK506-insensitive pathway triggered by yet-to-be-identified target cell surface molecules.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579455

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.

Authors:  Katia Chieregato; Cristina Zanon; Silvia Castegnaro; Martina Bernardi; Eliana Amati; Sabrina Sella; Francesco Rodeghiero; Giuseppe Astori
Journal:  Blood Transfus       Date:  2016-03-21       Impact factor: 3.443

2.  Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.

Authors:  Suradej Hongeng; Sawang Petvises; Surapon Worapongpaiboon; Busaba Rerkamnuaychoke; Samart Pakakasama; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Authors:  Selim Kuçi; Eva Rettinger; Bernhard Voss; Gerrit Weber; Miriam Stais; Hermann Kreyenberg; Andre Willasch; Zyrafete Kuçi; Ewa Koscielniak; Stephan Klöss; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

4.  MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells.

Authors:  Yu Chen; Jing Lin; Zeng-Qing Guo; Wan-Song Lin; Zhi-Feng Zhou; Chuang-Zhong Huang; Qiang Chen; Yun-Bin Ye
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

5.  A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

Authors:  B Hardy; R Kovjazin; A Raiter; N Ganor; A Novogrodsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R.

Authors:  You-Shun Zhang; Fang-Jun Yuan; Guo-Feng Jia; Ji-Fa Zhang; Li-Yi Hu; Ling Huang; Ju Wang; Zong-Qing Dai
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

7.  Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy.

Authors:  Yu Chen; Zeng-Qing Guo; Chun-Mei Shi; Zhi-Feng Zhou; Yun-Bin Ye; Qiang Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  Cytokine-induced killer cell therapy for the treatment of primary hepatocellular carcinoma subsequent to liver transplantation: A case report.

Authors:  Runmei Li; Fang Yan; Liang Liu; Hui Li; Baozhu Ren; Zhenzhen Hui; Xiubao Ren
Journal:  Oncol Lett       Date:  2016-01-14       Impact factor: 2.967

9.  A clinical study of cytokine-induced killer cells for the treatment of refractory lymphoma.

Authors:  Zhi Guo; Hao Liu; Xue-Peng He; Xiao-Hua Tan; Yan Zhou; Xia Chen; Yu-Jie Shi; Xiao-Dong Liu; Hui-Ren Chen
Journal:  Oncol Lett       Date:  2011-03-15       Impact factor: 2.967

10.  Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer.

Authors:  Yu Chen; Wan-Song Lin; Wei-Feng Zhu; Jing Lin; Zhi-Feng Zhou; Chuan-Zhong Huang; Gang Chen; Yi Shi; Zeng-Qing Guo; Yun-Bin Ye
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.